DXCM vs SENS

Dexcom maintains its strong position as a Continuous Glucose Monitoring (CGM) market leader, driven by successful G7 global rollout and promising initial penetration of Stelo into the Type 2 non-insulin market. The company exhibits solid financial health, consistent operational execution (Q4 2025 earnings beat), and positive analyst sentiment with recent upgrades. The absence of previous concerns ...

Senseonics (SENS) demonstrates strong operational execution with 87% YoY revenue growth in Q1 2026 and a strategic shift to direct European sales, strengthening its long-term competitive position. The unique 1-year Eversense sensor offers a significant market opportunity in the CGM space. However, the company continues to incur substantial net losses ($32.3M in Q1) and heavy cash burn. While recen...